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Abstract
Many viruses within the Flavivirus genus cause significant disease in humans; however, effective antivirals against these
viruses are not currently available. We have previously shown that a thiopurine drug, 6-methylmercaptopurine riboside
(6MMPr), inhibits replication of distantly related viruses within the Flaviviridae family in cell culture, including bovine viral
diarrhea virus and hepatitis C virus replicon. Here we further examined the potential antiviral effect of 6MMPr on several
diverse flaviviruses. In cell culture, 6MMPr inhibited virus production of yellow fever virus, dengue virus-2 (DENV-2) and West
Nile virus (WNV) in a dose-dependent manner, and DENV-2 was significantly more sensitive to 6MMPr treatment than WNV.
We then explored the use of 6MMPr as an antiviral against WNV in an immunocompetent mouse model. Once a day
treatment of mice with 0.5 mg 6MMPr was just below the toxic dose in our mouse model, and this dose was used in
subsequent studies. Mice were treated with 6MMPr immediately after subcutaneous inoculation with WNV for eight
consecutive days. Treatment with 6MMPr exacerbated weight loss in WNV-inoculated mice and did not significantly affect
mortality. We hypothesized that 6MMPr has low bioavailability in the central nervous system (CNS) and examined the effect
of pre-treatment with 6MMPr on viral loads in the periphery and CNS. Pre-treatment with 6MMPr had no significant effect
on viremia or viral titers in the periphery, but resulted in significantly higher viral loads in the brain, suggesting that the
effect of 6MMPr is tissue-dependent. In conclusion, despite being a potent inhibitor of flaviviruses in cell culture, 6MMPr was
not effective against West Nile disease in mice; however, further studies are warranted to reduce the toxicity and/or improve
the bioavailability of this potential antiviral drug.
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Introduction
The family Flaviviridae consists of three genera – Flavivirus,
Pestivirus and Hepacivirus. The genus Flavivirus contains multiple
important viral causes of human morbidity and mortality. For
example, the four serotypes of dengue virus (DENV-1, -2, -3 and -
4) infect more than 50 million people annually [1], and West Nile
virus (WNV) can cause severe neurologic disease with an
encephalitic case fatality rate of 18% [2]. Furthermore, there are
no effective antivirals against any of the flaviviruses.
Drugs that alter or inhibit purine metabolism such as ribavirin
and non-nucleoside inhibitors of inosine monophosphate dehy-
drogenase (IMPDH) inhibit flaviviruses in cell culture, but have
little to no effect in animal models of flavivirus infection [3,4,5].
GTP specifically is required for viral translation, transcription and
replication at higher concentrations than other nucleotide
triphosphates [6]. The thiopurine class of modified bases and
nucleosides [azathioprine, 6-mercaptopurine and 6-methylmer-
captopurine riboside (6MMPr), but not thioguanine] inhibits
replication of members of the Flaviviridae family with greater
inhibition of bovine viral diarrhea virus (BVDV; genus Pestivirus)
and hepatitis C virus (HCV; genus Hepacivirus) replicon than yellow
fever virus (YFV; genus Flavivirus) replicon [7,8]. The mechanisms
by which modified nucleosides inhibit replication of RNA viruses
include chain termination due to incorporation of modified
nucleosides into viral RNA, direct inhibition of viral polymerase,
inhibition of viral RNA capping, and mutagenesis of viral RNA
[9,10,11,12,13]. Modified nucleotides that lack 39 hydroxyls are
incapable of chain extension, but at least some nucleotides with 39
hydroxyls can be incorporated into nucleic acids and decrease the
speed of extension or functionally inhibit the polymerase process in
more subtle ways [14]. Clinical data suggest that the thiopurine,
azathioprine, is more protective than the IMPDH inhibitor,
mycophenolate, against HCV-mediated liver damage after liver
transplantation [15,16,17]. Here we showed that viral production
of both DENV and WNV was inhibited by 6MMPr although
DENV was more sensitive than WNV in cell culture. Despite the
sensitivity of WNV in cell culture, in a mouse model of WNV
infection, 6MMPr administration did not reduce morbidity or
mortality and resulted in higher viral loads in the brains of mice.
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6MMPr inhibits flavivirus production in multiple cell lines
We previously showed that 6MMPr is a potent inhibitor of
HCV replicon and BVDV in Huh7 cells [8]. We extended these
results by examining the effect of 6MMPr on viral growth for
members of the Flavivirus genus (DENV, YFV and WNV) in
several cell lines. Human hepatic and kidney cell lines were
inoculated with DENV-2 or YFV in the presence of various
concentrations of 6MMPr, and virus production was measured at
48 hours post-inoculation (hpi). Similar to our previous results for
BVDV, 6MMPr inhibited viral production for DENV-2 and YFV
by approximately 10-fold in Huh7 cells (Figure 1A). In addition,
6MMPr reduced viral production by 10-fold in Huh6 cells
(Figure 1B), 100-fold in HepG2 cells (Figure 1C), and 10,000-fold
in HEK293T cells (Figure 1D). The greater inhibition of viral
production in HEK293T cells was not due to drug cytotoxicity in
these cells (data not shown), which is consistent with our previous
results demonstrating that 6MMPr up to 500 mM does not cause
cytotoxicity in Madin-Darby bovine kidney cells [8].
We compared the antiviral effect of 6MMPr against DENV-2
and WNV – two distantly related flaviviruses. 6MMPr inhibited
viral production for both DENV-2 and WNV in a dose-dependent
manner at 48 hpi in Vero cells (Figure 2A). At maximum
inhibition (20–50 mM 6MMPr), DENV-2 was inhibited 1000-fold,
and WNV was inhibited 100-fold. At all concentrations tested,
6MMPr inhibited viral production for DENV-2 to a greater extent
than for WNV by approximately 10-fold (p,0.005), suggesting
that 6MMPr is a more effective inhibitor of DENV than WNV.
We confirmed these results by treating cells with 10 mM 6MMPr
and measuring production of infectious DENV-2 and WNV at
various times post-inoculation (pi). 6MMPr had a similar effect on
DENV-2 and WNV at 24 hpi, but inhibited DENV production
10- to 100-fold more than WNV production at 48 and 72 hpi,
respectively (Figure 2B). In conclusion, 6MMPr inhibited viral
production of two distantly related flaviviruses, and the efficiency
of inhibition was virus and cell type dependent. DENV-2 was
more sensitive to 6MMPr than WNV, and for DENV production,
6MMPr caused 10- to 100-fold greater inhibition in the two
kidney cell lines (HEK293T and Vero) than in the two liver cell
lines (Huh 7 and Huh 6), which may reflect differences in cell
growth or inherent differences in cell types.
Treatment of mice with 6MMPr
We explored the use of 6MMPr as an antiviral against WNV in
a well-characterized immunocompetent mouse model, using the
highly susceptible C3H/HeN (C3H) mouse strain [18]. A
previous report showed that BUB mice tolerate treatment with
80 mg/kg/day 6MMPr for 10 consecutive days [19]; therefore,
we opted to test a lower dose to avoid toxicity. We treated C3H
mice once per day with vehicle alone or 0.5 mg 6MMPr
(approximately 25 mg/kg/day) intraperitoneally (IP) for 10 days,
and no clinical signs of toxicity or weight loss greater than 5%
were observed (data not shown). 6MMPr has a short half-life in
mice [20]; therefore, we tested twice per day treatment in a
subsequent study to attempt to maintain drug levels. Mice were
treated twice per day with vehicle alone, 0.25 mg 6MMPr
(approximately 25 mg/kg/day; low dose group), or 0.5 mg
6MMPr (approximately 50 mg/kg/day; high dose group) for
seven consecutive days, and mice were weighed daily. Weight loss
of greater than 10% was observed in all of the mice in the high
dose group and half of the mice in the low dose group, but no
weight loss was observed in the vehicle treated group (data not
shown). These results suggest that once per day treatment with
0.5 mg 6MMPr is just below a toxic dose for C3H mice, and this
dose was then used in subsequent antiviral studies.
We determined the effect of 6MMPr on morbidity and
mortality following subcutaneous (SC) inoculation with 10
3 PFU
of WNV with treatment starting immediately prior to virus
inoculation. Mice were treated once daily with vehicle control or
0.5 mg 6MMPr for eight consecutive days (days 0–7 pi relative to
WNV inoculation). All WNV-inoculated mice (vehicle-treated and
6MMPr-treated) exhibited clinical signs of disease, and there were
no significant differences in disease onset or mortality between the
vehicle-treated and 6MMPr-treated mice (Table 1). Furthermore,
treatment with 6MMPr had no significant effect on survival of the
WNV-inoculated mice (P=0.75) (Figure 3A). 6MMPr treatment
resulted in weight loss in both the mock-inoculated and WNV-
inoculated mice with an average 10% weight loss after eight daily
treatments, and 6MMPr treatment exacerbated weight loss due to
West Nile disease, starting on day 8 pi (Figure 3B). These results
demonstrate that treatment with 6MMPr did not reduce morbidity
or mortality due to West Nile disease and resulted in mild toxicity
manifested as weight loss.
Possible explanations for the lack of effectiveness against West
Nile disease by 6MMPr include low drug concentrations during
early WNV infection and/or poor bioavailability in the central
nervous system (CNS). Thus, we conducted a study to examine the
effect of 6MMPr pretreatment on viral loads in the periphery and
CNS. Mice were pretreated with vehicle or 0.5 mg 6MMPr once
per day for seven consecutive days, starting one day prior to viral
inoculation, and viral titers were determined in serial bleeds from
days 1, 2, 3, and 4 pi and in tissues harvested on day 6 pi. The
6MMPr-treated group had a 2-fold lower geometric mean titer at
peak viremia (2 days pi) than the vehicle-treated group, but the
difference was not significant (P=0.085) (Figure 4A). Treatment
with 6MMPr resulted in significantly higher viral loads in brains
(P=0.013), but not in spinal cords, skin at the inoculation site,
draining lymph nodes, and spleen (Figure 4B). Weight loss was
again observed in the 6MMPr-treated mice with significantly
greater losses on days 3–6 pi in the WNV-inoculated mice
compared to the mock-inoculated mice (P,0.05) (Figure 4C),
which was most likely due to the combined stress of viral infection,
serial bleeding, and drug treatment. In conclusion, treatment with
6MMPr had no significant effect on viremia or viral loads in the
periphery, but it enhanced viral loads in the brain, suggesting that
the effect of 6MMPr is tissue dependent in the mouse model.
Discussion
In this work we have extended our observations that not only
pestiviruses (e.g. BVDV) and hepaciviruses (e.g. HCV) are
inhibited by thiopurines in mammalian cell culture [7,8], but
several distantly related flaviviruses (e.g. DENV-2, YFV and
WNV) are as well. We previously presented data showing that the
HCV replicon is more susceptible to inhibition by 6MMPr than a
YFV replicon, and our current studies with the complete life cycle
of YFV showed that YFV had similar susceptibility as DENV-2
(Figure 1). We tested multiple DENV-2 strains, including 16681
(Figure 1), New Guinea C (Figure 2), and S1 (data not shown), and
a DENV-4 strain (data not shown), and there was no difference in
sensitivity between DENV strains. On the other hand, DENV-2
was 10-fold more sensitive than WNV to 6MMPr treatment. One
potential explanation for this difference is that the replication
kinetics of WNV are faster than DENV and, therefore, less altered
by the effect of 6MMPr on cell growth. Another possibility that is
not mutually exclusive with the effect on cell growth is that there
are small differences between the conserved DENV and WNV
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regulate replication. Numerous groups have shown that non-
nucleoside IMPDH inhibitors, such as mycophenolic acid, inhibit
the flaviviruses DENV, YFV, and WNV [23,24,25], but
susceptibility differences between flaviviruses have not been
reported. While both mycophenolic acid and thiopurines have
cytostatic effects and block purine synthesis, their mechanisms
differ. Thiopurines decrease purine synthesis through inhibition of
glutamine-5-phosphoribosylpyrophosphate aminotransferase [26],
and mycophenolic acid inhibits purine synthesis by inhibiting
IMPDH [27].
Although DENV is more susceptible to thiopurine inhibition in
cell culture, we chose to test the effect of 6MMPr on WNV in a
mouse model because infection of mice with WNV is a well-
characterized, relatively inexpensive immunocompetent system
from which both mortality and viral load data can be obtained.
Treatment with 6MMPr had no significant effect on production of
infectious virus in the skin at the inoculation site, draining lymph
node, spleen and spinal cord, but resulted in significantly greater
viral titers in the brain. Possible explanations for these tissue
differences include low drug concentrations in the brain, poor
efficacy of 6MMPr in neurons of the brain, and disruption of the
blood brain barrier by 6MMPr, changing the kinetics of
neuroinvasion. Future experiments are required to explore these
possibilities.
We were surprised both by the toxicity that we observed from
6MMPr in WNV-infected animals, as well as the milder toxicity/
weight loss seen in the uninfected animals. 6MMPr has been
administered in humans in combinations with other antimetabolite
chemotherapy [28,29,30] as well as in mice [19] with less toxicity
than we observed. The mouse strain we used (C3H) differed from
the limited published literature on 6MMPr in mice [19], but other
thiopurines, such as azathioprine, have been extensively used in
mice without causing weight loss. Recent data show azathiaprine
triggers erythropoiesis and works against malaria in cell culture
and in mice [31]. 6MMPr is a downstream metabolite of
azathioprine and presumably would have similar toxicity, but
perhaps 6MMPr is less toxic when produced in situ from a
precursor. After liver transplants, whether patients have HCV or
not, they are given a cocktail of two to three immunosuppressants
to prevent rejection that typically includes either the IMPDH
inhibitor, mycophenolate, or the thiopurine, azathioprine. It is
unclear whether the differences between these two types of
immunosuppressants on HCV posttransplant [14,15,16] are due
to their effect on cellular biosynthetic pathways or differences in
the degree to which the immune system is suppressed.
In conclusion, despite the potent antiviral effects of 6MMPr on
flaviviruses in cell culture, in a mouse model of WNV, 6MMPr
exacerbates weight loss and increases viral loads in the brain,
possibly due to poor bioavailability in the central nervous system.
While 6MMPr may be useful in probing differences in replication
among flaviviruses, clearly more selective antiviral activity is
necessary for safe therapy for WNV. Finally, future development
as an antiviral against DENV is warranted since DENV is rarely
Figure 1. 6MMPr inhibited DENV and YFV production in
multiple cell lines in a dose-dependent manner. (A) Huh7, (B)
Huh6, (C) HepG2, and (D) HEK293T cells were inoculated with DENV-2
(16681) or YFV in the presence of various concentrations of 6MMPr.
Medium was harvested at 48 hpi, and viral titers were determined by
fluorescent focus assays. At least two independent experiments were
performed, and the means 6 standard deviations from one experiment,
performed in triplicate, are shown.
doi:10.1371/journal.pone.0026697.g001
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against DENV, suggesting a greater therapeutic window.
Materials and Methods
Ethics statement
Mouse studies were performed under strict accordance of the
criteria established by the National Institutes of Health, and all
efforts were made to minimize suffering. The protocols were
approved by the Institutional Animal Care and Use Committees of
the Wadsworth Center (protocol #09-377) or the University of
Wisconsin-Madison (protocol #V01452).
Cells
African green monkey kidney cells (Vero; ATCC #CCL-81)
and baby hamster kidney cells (BHK-21; ATCC #CCL-10) were
maintained in minimum essential medium (Gibco-Invitrogen,
Carlsbad, CA) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) , 2 mM L-glutamine, 1.5 g/L sodium
bicarbonate, 100 U/ml penicillin, and 100 mg/ml streptomycin.
Human embryonic kidney cells (HEK 293T; ATCC #CRL-
11268), human hepatocellular carcinoma cells HepG2 (ATCC
#59194) and Huh7 (JCRB0403), and human hepatoblastoma cells
Huh6 (JCRB0401) were maintained in Dulbecco’s modified Eagle
medium (Gibco-Invitrogen) supplemented with 10% FBS, 100 U/
ml penicillin, and 100 mg/ml streptomycin. Aedes albopictus
mosquito cells (C6/36; ATCC #CRL-1660) were maintained in
L-15 medium (Gibco-Invitrogen) supplemented with 10% FBS,
100 U/ml penicillin, and 100 mg/ml streptomycin. All mamma-
lian cells were incubated at 37uC, 5% CO2, and mosquito cells
were incubated at 28uC, 5% CO2.
Viruses
WNV was produced from a full-length cDNA clone of a 2000
New York strain by electroporation of BHK-21 cells with in vitro
transcribed RNA as previously described [32]. Viral titers of
WNV were determined by plaque assay on Vero cells. DENV-2
strain New Guinea C and DENV-2 strain 16681 (Genbank
accession number U87411) were obtained from the Centers for
Disease Control and Prevention (CDC, Fort Collins, CO).
DENV-2 (New Guinea C) was prepared in Vero cells as
previously described [33]. DENV-2 strain 16681 was prepared
by infecting C6/36 cells at a multiplicity of infection of 10 in L-15
medium with 100 U/ml penicillin and 100 mg/ml streptomycin.
Figure 2. 6MMPr inhibited DENV production to a greater extent than WNV production. Vero cells were inoculated with WNV or DENV-2
(New Guinea C) in the presence of 6MMPr at (A) various concentrations or at (B) 10 mM. Medium was harvested at (A) 48 hpi or (B) various times pi,
and viral titers were determined by plaque assays. At least two independent experiments were performed, and the means 6 standard deviations
from one experiment, performed in (A) sextuplets or (B) triplicates, are shown. The antiviral effects on WNV and DENV-2 were compared at each
concentration of 6MMPr in (A), and P values were #0.005 at all concentrations tested (1–50 mM).
doi:10.1371/journal.pone.0026697.g002
Table 1. Treatment with 6MMPr did not affect morbidity or mortality in WNV-inoculated mice.
Virus inoculum Treatment
Clinical Signs
(no. sick/total)
Average disease onset
(SD) (days)
Mortality
(no. died/total)
Average survival
time (SD) (days)
Diluent Vehicle 0/4 NA 0/4 NA
Diluent 6MMPr 0/4 NA 0/4 NA
WNV Vehicle 8/8 9.2 (1.3) 6/8
1 11.8 (2.5)
2
WNV 6MMPr 8/8 9.9 (2.2) 8/8 12.1 (2.4)
Adult, female C3H mice were inoculated SC in the left rear footpad with diluent or 10
3 PFU WNV. Mice were treated for eight days with vehicle or 0.5 mg 6MMPr IP once
per day starting immediately prior to virus inoculation. Mice were monitored for weight loss and clinical signs.
1Two mice that survived WNV infection seroconverted to WNV by day 28 pi.
2Only mice that died were included in the calculation. NA=not applicable. SD=standard deviation.
doi:10.1371/journal.pone.0026697.t001
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make 2% final concentration. Supernatants were harvested on
day 5 pi, clarified by centrifugation (5006g for 5 min), and stored
in aliquots at 280uC. YFV strain PFLYF17D (Genbank
accession number X03700) was prepared from a full-length
cDNA clone [34] by transfection of Huh7 with in vitro transcribed
RNA using Mirus TransIT RNA Transfection Kit (Mirus Bio,
Madison, WI), as per manufacturer’s instruction. Viral titers of
DENV-2 and YFV stocks were determined by fluorescent focus
assays on Vero cells.
Fluorescent focus assay
Fluorescent focus assay was modified from a previous report
[33]. Briefly, 48-well plates were seeded with Vero cells at a
density of 5610
4 cells/well and incubated at 37uC. After 24 hpi,
cells were inoculated with 10-fold serial dilutions of virus for 1 h at
37uC, and then an overlay medium containing 0.5% agarose,
0.56 Earle’s Balanced Salt solution, 0.033% Yeast Extract,
0.165% lactalbumin hydrolysate, 4% FBS, 0.225% sodium
bicarbonate, 50 U/ml penicillin, and 50 mg/ml streptomycin
was added. After 48 h at 37uC, cells were fixed with 1:1
methanol:acetone solution for 10 min and incubated with mouse
ascites fluid against DENV (1:500 dilution; Harlan, Madison, WI)
or antibody against YFV (Clone 2D12.A; 1:800 dilution;
Millipore, Billerica, MA) in phosphate buffered saline (PBS) with
0.2% bovine serum albumin for 1 h at room temperature,
followed by donkey anti-mouse IgG conjugated with Alexa-Fluor
488 (1/200 dilution; Invitrogen, Carlsbad, CA) for 30 min at room
temperature. Fluorescent foci were observed using a Nikon Eclipse
TE300 microscope (Melville, NY), and foci within the entire well
were counted and expressed as focus forming units (FFU) per ml.
Effect of 6MMPr on virus growth in cell culture
Approximately 4610
4 cells/well were added to 24-well plates
and incubated for 24 h at 37uC. Cells were rinsed with PBS and
inoculated with 10
4 PFU or FFU of virus (multiplicity of infection
of approximately 0.25 based on titration on Vero cells).
Immediately after the addition of virus, 6MMPr (Sigma-Aldrich,
St Louis, MO) was added to the cultures in the appropriate
medium without FBS. After 1 h incubation at 37uC, FBS was
added to make a 2% final concentration of FBS, and cells were
incubated at 37uC. At various times pi, supernatants were
collected and stored at 280uC. Virus production was determined
by fluorescent focus assays or plaque assays on Vero cells.
Antiviral studies in mice
Five-week-old, female C3H mice were purchased from Taconic
(Germantown, NY), acclimatized for at least 1 week in the
biosafety-level-3 animal facility, and given food and water ad
libitum. 6MMPr was dissolved in sterile PBS (tissue culture grade;
Invitrogen) immediately before treatment of mice for all studies.
Mice were inoculated IP with 100 ml of sterile PBS (vehicle
control) or 100 ml of 6MMPr once or twice per day at the
designated dose. Mice were weighed and clinically assessed daily.
Percentage initial weight was calculated to evaluate weight loss,
and 10% weight loss was considered significant. No clinical signs
of drug toxicity, such as ruffled fur, hunching, weakness, labored
breathing, ascites or abdominal irritation, were observed in any of
the studies.
For the morbidity and mortality study, six- to seven-week-old
C3H mice (14.7–19.7 g, mean weight of 17.4 g) were treated with
PBS (vehicle control) or 6MMPr (0.5 mg/mouse) once daily for
eight consecutive days. Immediately after the first treatment, mice
were inoculated SC in the left rear footpad with diluent alone
(mock; n=4 per group) or 10
3 PFU of WNV (n=8 per group) as
previously described [18]. Mice were monitored daily for weight
loss and clinical signs, and mice with severe disease were
euthanized. Clinical signs included ruffled fur, hunching, weakness
and ataxia. A mouse was considered to have clinical West Nile
disease if at least one of the following criteria was met: 1)$10%
Figure 3. 6MMPr treatment of mice did not improve survival and exacerbated weight loss during WNV infection. Adult, female C3H
mice were treated with vehicle or 0.5 mg 6MMPr once daily for eight consecutive days (days 0 to 7 pi). Immediately after the first treatment, mice
were inoculated SC in the left rear footpad with diluent alone (mock; n=4 per group) or with 10
3 PFU of WNV (n=8 per group) and monitored daily
for weight loss and clinical signs. (A) Survival data are shown. Viral infection was confirmed in all WNV-inoculated survivors by seroconversion to WNV.
(B) The means 6 standard deviations of percentage initial weight are shown. Significant P values between mock-inoculated, 6MMPr-treated mice and
WNV-inoculated, 6MMPr-treated mice are indicated as follows: *, P,0.05; **, P,0.005.
doi:10.1371/journal.pone.0026697.g003
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was confirmed in all WNV-inoculated survivors by the detection of
antibodies to WNV as previously described [18].
For evaluation of viral loads in sera and tissues, six- to seven-
week-old C3H mice (16.6–19.8 g, mean weight of 18.3 g) were
treated with PBS or 6MMPr (0.5 mg/mouse) for seven consecu-
tive days, and treatment was begun one day prior to viral
inoculation. Mice were inoculated with diluent (n=3–4 per group)
or WNV (n=8 per group) as described above, weighed daily, and
serially bled three times via puncture of the maxillary vein. Half of
the mice in each group was bled on days 1, 2 and 3 pi, and the
other half was bled on days 2, 3 and 4 pi, resulting in 4 mice per
group on days 1 and 4 and 8 mice per group on days 2 and 3. On
day 6 pi, mice were euthanized, and tissues were harvested and
stored at 270uC. Tissues were processed as previously described
[18], and viral loads in sera and tissues were determined by plaque
assays on Vero cells. Infectious virus was not detected in mock-
inoculated mice.
Figure 4. The effect of 6MMPr treatment of mice during WNV infection was tissue dependent. Adult, female C3H mice were pre-treated
with vehicle or 6MMPr once daily for seven consecutive days (days 21 to 5 pi). On day 0, mice were inoculated SC with diluent alone (mock; n=3–4
per group) or 10
3 PFU of WNV (n=8 per group). Mice were weighed daily, serially bled three times between days 1–4 pi (for WNV-inoculated mice,
n=4 per group on days 1 and 4 pi and n=8 per group on days 2 and 3 pi), and euthanized on day 6 pi when tissues were harvested. (A) The
geometric means 6 standard deviations of virus titers in sera are shown. (B) Viral loads in tissues on day 6 pi are shown. Each data point represents
an individual mouse, and the horizontal solid lines represent the geometric means. (C) The means 6 standard deviations of the percentage initial
weight are shown, and significant P values between mock-inoculated, 6MMPr-treated mice and WNV-inoculated, 6MMPr-treated mice are indicated:
*, P,0.05. For (A) and (B), significant P values between vehicle and 6MMPr treated mice inoculated with WNV are noted on the graphs, and the
dashed lines represent limits of detection of (A) 500 PFU/mL or (B) 500 PFU/g for skin, draining lymph nodes and spleen and 250 PFU/g for brain and
spinal cord. Data points below the dashed lines are less than the limit of detection for the plaque assay.
doi:10.1371/journal.pone.0026697.g004
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A two-tailed Mann-Whitney U test (GraphPad, San Diego, CA)
was used to test for differences between the effect of 6MMPr on
DENV and WNV growth in cell culture, viral loads in serum and
tissues, and weight loss. Values of 333 PFU/ml for serum and
peripheral tissues and 100 PFU/g for brain and spinal cord were
used to calculate the geometric means and standard deviations for
any samples below the limit of detection for the plaque assays. A
log-rank survival analysis (GraphPad) was used to test for the effect
of treatment on survival. For all analyses, a P value#0.05 was
considered significant.
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